Foamix Pharmaceuticals Ltd (FOMX) Stake Boosted by Van ECK Associates Corp

Van ECK Associates Corp lifted its stake in shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 75.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 19,752 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,474 shares during the period. Van ECK Associates Corp’s holdings in Foamix Pharmaceuticals were worth $71,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Perceptive Advisors LLC grew its stake in shares of Foamix Pharmaceuticals by 178.1% during the 3rd quarter. Perceptive Advisors LLC now owns 3,107,424 shares of the specialty pharmaceutical company’s stock worth $17,806,000 after purchasing an additional 1,990,100 shares during the period. Franklin Resources Inc. grew its stake in Foamix Pharmaceuticals by 55.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,321,745 shares of the specialty pharmaceutical company’s stock valued at $13,304,000 after acquiring an additional 826,200 shares during the last quarter. AXA grew its stake in Foamix Pharmaceuticals by 43.8% in the 3rd quarter. AXA now owns 1,369,341 shares of the specialty pharmaceutical company’s stock valued at $7,846,000 after acquiring an additional 416,787 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Foamix Pharmaceuticals in the 3rd quarter valued at about $6,616,000. Finally, Sio Capital Management LLC acquired a new stake in Foamix Pharmaceuticals in the 3rd quarter valued at about $4,412,000. 60.60% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on FOMX shares. HC Wainwright set a $12.00 price objective on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 4th. Bank of America started coverage on shares of Foamix Pharmaceuticals in a research note on Wednesday, December 12th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, Cowen set a $30.00 price objective on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Foamix Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $14.69.

Shares of NASDAQ FOMX opened at $3.92 on Friday. The stock has a market capitalization of $213.12 million, a P/E ratio of -2.31 and a beta of 1.68. Foamix Pharmaceuticals Ltd has a 52 week low of $3.21 and a 52 week high of $7.60.

In other Foamix Pharmaceuticals news, insider Matthew T. Wiley acquired 13,440 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were purchased at an average cost of $3.76 per share, with a total value of $50,534.40. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 3.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Foamix Pharmaceuticals Ltd (FOMX) Stake Boosted by Van ECK Associates Corp” was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2019/03/17/foamix-pharmaceuticals-ltd-fomx-stake-boosted-by-van-eck-associates-corp.html.

Foamix Pharmaceuticals Profile

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Read More: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding FOMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX).

Institutional Ownership by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply